On December 16, 2020 Luminex Corporation (Nasdaq: LMNX) reported that Nachum "Homi" Shamir, Chairman, CEO and President, and Harriss Currie, Senior Vice President and CFO, will present at the 39th Annual J.P. Morgan Healthcare Conference, to be held virtually, on January 13, 2021 at 3:30 p.m. Central Time (Press release, Luminex, DEC 16, 2020, View Source [SID1234572954]). A live webcast of the Luminex presentation may be accessed at the company’s website at View Source The presentation will be archived for six months on the website using the ‘replay’ link.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On December 16, 2020 Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, reported that it has been selected for addition to the NASDAQ Biotechnology Index (Nasdaq: NBI), effective prior to market open on Monday, December 21, 2020 (Press release, Jounce Therapeutics, DEC 16, 2020, View Source [SID1234572938]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The NASDAQ Biotechnology Index is designed to track the performance of a set of securities listed on The Nasdaq Stock Market (NASDAQ) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark. All securities in the index are listed on the NASDAQ Global Market or the NASDAQ Global Select Market and must meet eligibility requirements, including minimum market capitalization, average daily trading volume, seasoning as a public company, among other criteria.

The NASDAQ Biotechnology Index is re-ranked annually and forms the basis for a number of Exchange Traded Funds (ETFs), including the iShares NASDAQ Biotechnology ETF. More information about the Index can be found at View Source

On December 16, 2020 Amphivena Therapeutics, a clinical-stage oncology company focused on developing a platform of bivalent T-cell engagers that restore anti-cancer immunity in patients, reported the first patient has been dosed in the Phase 1 dose expansion study evaluating AMV564, an investigational, first-in-class agent that depletes myeloid derived suppressor cells (MDSC) and activates T cells, in adult patients with selected solid tumor indications (Press release, Amphivena Therapeutics, DEC 16, 2020, View Source [SID1234572955]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The dose escalation phase of the first-in-human, multicenter, open-label study of AMV564 in solid tumors was initiated in October 2019 and established the safety, PK profile and clinical activity of AMV564 including a confirmed RECIST complete response.

The dose expansion study will explore AMV564 as a monotherapy in tumor-specific cohorts selected to enrich for patients with actionable antigens. The primary objectives of the study are to further characterize the safety and tolerability and to evaluate preliminary efficacy of AMV564 monotherapy administered subcutaneously.

"AMV564 has demonstrated an excellent safety profile and encouraging preliminary activity in heavily pretreated patients, and we look forward to seeing how this novel mechanism translates to clinical benefit in selected cancer patient populations including patients with inadequate benefit from checkpoint inhibitors, representing an area of high unmet need," said Curtis Ruegg, Ph.D., President and Chief Executive Officer of Amphivena Therapeutics.

The trial is being conducted at a planned 15 sites in the United States. Additional information on this trial, including comprehensive inclusion and exclusion criteria, can be accessed at www.ClinicalTrials.gov (NCT04128423).

About AMV564

AMV564 relieves immune suppression via targeted depletion of immunosuppressive MDSC and drives T cell activation and polarization to restore anti-cancer immunity. To date, over 95 patients have received AMV564 across three Phase 1 clinical trials for patients with solid tumors, acute myeloid leukemia (AML), and myelodysplastic syndromes (MDS).

On December 16, 2020 Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), reported that it has entered a collaboration enabling the use by AC Bioscience LTD of preclinical and clinical data for LX2931 without granting any right or license under any of Lexicon’s patent rights for the compound (Press release, Lexicon Pharmaceuticals, DEC 16, 2020, View Source [SID1234572939]). LX2931 is a small molecule sphingosine-1-phosphate (S1P) lyase inhibitor that is currently not in active development at Lexicon.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"In line with our realignment around the rapid development of the LX9211 program, we continue to evaluate our pipeline and determine the most effective way to advance our broad library of compounds and targets," said Praveen Tyle, Ph.D., executive vice president of research and development. "We are pleased to collaborate with AC Bioscience to accelerate their efforts around S1P and look forward to learning additional information about this potentially interesting pathway."

Under the terms of the agreement, Lexicon will receive an upfront payment and is eligible to receive milestone payments totaling up to $5.3 million in the aggregate.

On December 16, 2020 Qualigen Therapeutics, Inc. (NASDAQ: QLGN) ("Qualigen" or the "Company"), reported it has entered into a definitive agreement with a single institutional investor for the purchase and sale for $12,000,000 of (i) 2,370,786 Common Shares, (ii) 1,000,000 Pre-Funded Warrants (iii) 1,348,314 Common Warrants exercisable immediately and (iv) 842,696 Common Warrants exercisable six (6) months after issuance at a combined purchase price of $3.56 in a registered direct offering (Press release, Qualigen, DEC 16, 2020, View Source [SID1234572956]). The Common Warrants will have an exercise price of $4.07 per share and have a term of two years. The closing of the offering is expected to occur on or about December 18, 2020, subject to the satisfaction of customary closing conditions.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A.G.P./Alliance Global Partners is acting as sole placement agent for the offering.

This offering is being made pursuant to an effective shelf registration statement on Form S-3 (File No. 333-232798) previously filed with the U.S. Securities and Exchange Commission (the "SEC"). A prospectus supplement describing the terms of the proposed offering will be filed with the SEC and will be available on the SEC’s website located at View Source Electronic copies of the prospectus supplement may be obtained, when available, from A.G.P./Alliance Global Partners, 590 Madison Avenue, 28th Floor, New York, NY 10022, or by telephone at (212) 624-2060, or by email at [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.